EUVIMEDEUVIMED entdecken
Crossref

Characterization of patients with rheumatoid arthritis not using biologic/targeted synthetic disease-modifying drugs despite insufficient disease control: Another difficult-to-treat RA

Hisakata Yamada iD, Ryosuke Tsurui, Masakazu Kondo, Jun-Ichi Fukushi, Koji Sakuraba, Tomoya Miyamura, Motoko Ishida, Masataka Nakamura, Yasushi Inoue, Tomomi Tsuru, Toshihide Shuto, Seiji Yoshizawa und 16 weitere

Modern Rheumatology · 2025

DOI: 10.1093/mr/roaf037 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Modern Rheumatology, 2025. Verfasst von Hisakata Yamada und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Immunology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Antirheumatic Agents, Biological Products. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 17 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To understand the prevalence and characteristics of rheumatoid arthritis (RA) patients not using biologic/targeted synthetic disease-modifying drugs (b/tsDMARDs) despite insufficient disease control.

Methods

The data from 3172 RA patients in the FRANK (Fukuoka RA NetworK) registry, a Japanese registry of RA patients, were analysed. The patients were divided into groups based on the use of b/tsDMARDs and the reasons for not using them. Age, disease duration, drug use, activity of daily living (ADL) and quality of life (QOL) measures, the frequency of workers, and satisfaction with treatment were compared among the groups.

Results

About 10% of RA patients in the FRANK registry are non-users of b/tsDMARDs despite disease activity. The three major reasons for not using were the presence of comorbidity, economic reasons, and the patient’s intent except for economic reasons. Patients with comorbidity and/or older age have low ADL/QOL but are mostly satisfied with the treatment. Intriguingly, patients not using b/tsDMARDs due to economic reasons are the youngest and have the highest proportion of workers.

Conclusions

We revealed the status of RA patients, non-users of b/tsDMARDs despite disease activity, who are not included in the European Alliance of Associations for Rheumatology (EULAR)-defined difficult-to-treat RA. About half of them might benefit from b/tsDMARD by patient education and socioeconomic support.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, RheumatoidAntirheumatic AgentsBiological ProductsHumansMaleFemaleMiddle AgedAgedQuality of LifeRegistriesActivities of Daily LivingAdultJapanPatient Satisfaction

Stichwörter der Autor:innen

Japaneseb/tsDMARDepidemiologyregistryrheumatoid arthritis

Substanzen

Antirheumatic AgentsBiological Products

Autor:innen und Institutionen

  • Department of Clinical Immunology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Department of Orthopaedic Surgery, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.
  • Kondo Clinic of Rheumatology and Orthopaedic Surgery, Fukuoka, Japan.
  • Department of Orthopedics Surgery and Rheumatology, NHO Kyushu Medical Center, Fukuoka, Japan.
  • Department of Internal Medicine and Rheumatology, NHO Kyushu Medical Center, Fukuoka, Japan.
  • Department of Rheumatology, Japanese Red Cross Fukuoka Hospital, Fukuoka, Japan.

ORCID-Profile: Hisakata Yamada

Zitieren

APA

Yamada, H., Tsurui, R., Kondo, M., Fukushi, J. I., Sakuraba, K., Miyamura, T., Ishida, M., Nakamura, M., Inoue, Y., Tsuru, T., Shuto, T., Yoshizawa, S., Ohishi, M., Kamo, K., Haraguchi, A., Maeyama, A., Arinobu, Y., Mitoma, H., Ayano, M., …, & Nakashima, Y. (2025). Characterization of patients with rheumatoid arthritis not using biologic/targeted synthetic disease-modifying drugs despite insufficient disease control: Another difficult-to-treat RA. Modern Rheumatology. https://doi.org/10.1093/mr/roaf037

Vancouver

Yamada H, Tsurui R, Kondo M, Fukushi JI, Sakuraba K, Miyamura T, et al. Characterization of patients with rheumatoid arthritis not using biologic/targeted synthetic disease-modifying drugs despite insufficient disease control: Another difficult-to-treat RA. Modern Rheumatology. 2025. doi:10.1093/mr/roaf037

BibTeX
@article{Yamada2025,
  author = {Yamada, Hisakata and Tsurui, Ryosuke and Kondo, Masakazu and Fukushi, Jun-Ichi and Sakuraba, Koji and Miyamura, Tomoya and Ishida, Motoko and Nakamura, Masataka and Inoue, Yasushi and Tsuru, Tomomi and Shuto, Toshihide and Yoshizawa, Seiji and Ohishi, Masanobu and Kamo, Kenta and Haraguchi, Akihisa and Maeyama, Akiza and Arinobu, Yojiro and Mitoma, Hiroki and Ayano, Masahiro and Ono, Nobuyuki and Akasaki, Yukio and Fujiwara, Toshifumi and Hara, Daisuke and Arisumi, Shinkichi and Yasumoto, Keitaro and Natori, Takahiro and Niiro, Hiroaki and Nakashima, Yasuharu},
  title = {Characterization of patients with rheumatoid arthritis not using biologic/targeted synthetic disease-modifying drugs despite insufficient disease control: Another difficult-to-treat RA},
  journal = {Modern Rheumatology},
  year = {2025},
  doi = {10.1093/mr/roaf037}
}
Kostenlos starten →